Advances in Personalized Medicine and Immuno-oncologyVideo Categories: Personalized Medicine
Dr. Mauro addresses the debate over selecting first line therapy with three approved agents available.
Dr. David S. Siegel discusses the importance of understanding the molecular biology of myeloma. Physicians can now look at and offer alternative treatments to patients that they identify will most likely do poorly with traditional treatment. He believes this area will develop quickly over the next 2 to 5 years.